Subscribe
gavel-istock-508411976_andreypopov
AndreyPopov / iStockphoto.com
19 June 2017Americas

Federal Circuit invalidates cardiovascular diagnostics patents

The US Court of Appeals for the Federal Circuit has affirmed a district court’s ruling in a dispute over diagnostic tests for cardiovascular diseases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Medicure and Nexus agree Aggrastat generic licence
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

More on this story

Americas
Medicure and Nexus agree Aggrastat generic licence
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

More on this story

Americas
Medicure and Nexus agree Aggrastat generic licence
20 November 2020   US cardiovascular therapies company Medicure has settled a patent infringement dispute with rival Nexus Pharmaceuticals.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?